Abstract 192P
Background
Selective FGFR inhibitors are approved for treatment (tx) of FGFR+ advanced urothelial cancer (UC) and cholangiocarcinoma (CCA). The prognostic FGFR+ impact in solid tumors shows mixed results for select solid tumor types (TT). This study assessed the real-world (RW) prognostic impact of FGFR+ on overall survival (OS) of patients (pts) in a tumor agnostic (TA) setting.
Methods
This retrospective study used the Flatiron/Foundation Medicine, Inc Clinico-genomic database (FMI), including data from ∼280 US cancer centers. Pts (age ≥18 y) had advanced/metastatic (adv/met) disease (except UC), evidence of FGFR testing, and started first-line (1L) systemic tx in the adv/met setting. All pts had FMI's tissue-based genomic profiling. Pts with prior selective FGFR inhibitor tx were excluded. FGFR+ was defined as ≥1 of 81 prespecified FGFR oncogenic mutations or any FGFR fusion involving an intact kinase domain. Pts with wildtype FGFR (FGFR-) were matched 3:1 with pts with FGFR+ on TT, age, sex, date of adv/met disease diagnosis, and FMI test version. The statistically powered primary objective assessed differences in TA RW OS from 1L tx initiation in pts with FGFR+ vs FGFR- adv/met disease treated with standard of care systemic tx. Secondary objectives assessed differences in tumor specific RW OS and in time to tx discontinuation or to next tx. Delayed entry models and covariate-adjusted stratified Cox models were used to mitigate bias.
Results
Data from 253 FGFR+ and 759 FGFR- pts were analyzed. Demographics, baseline disease and clinical characteristics were balanced between groups. There were no significant differences in TA RW OS from 1L between groups (HR, 0.97 [FGFR+ vs FGFR-]; p=0.78). Median RW OS from initiation of 1L tx was 1.13 y (95% CI, 0.92-1.52) and 1.01 y (95% CI, 0.89-1.15) for FGFR+ and FGFR- pts, respectively. There were no significant differences in RW OS between groups in tumor-specific comparisons, including CCA, breast cancer, and NSCLC.
Conclusions
There was no statistically significant difference in RW OS between pts with FGFR+ or FGFRadv/ met solid tumors, with a median OS of ∼1 year in both groups. These results highlight the poor prognosis and high unmet need for novel, targeted tx.
Clinical trial identification
Editorial acknowledgement
Frank Derosa, Parexel.
Legal entity responsible for the study
Janssen Research and Development.
Funding
Janssen Research and Development.
Disclosure
H. Sweiti: Financial Interests, Institutional, Stocks or ownership: Janssen R&D; Financial Interests, Institutional, Full or part-time Employment: Janssen R&D. L. Demirdjian: Financial Interests, Institutional, Full or part-time Employment: Janssen Research and Development; Financial Interests, Institutional, Stocks/Shares: Janssen Research and Development; Financial Interests, Institutional, Other, Patent: Janssen Research and Development; Non-Financial Interests, Project Lead: Janssen Research and Development. S. Triantos: Financial Interests, Institutional, Full or part-time Employment: Janssen R&D; Financial Interests, Institutional, Stocks or ownership: Janssen R&D. K. Standish: Financial Interests, Institutional, Full or part-time Employment: Johnson and Johnson, Merck; Financial Interests, Institutional, Stocks or ownership: Johnson and Johnson, Merck, Eli Lilly; Financial Interests, Institutional, Research Funding: Johnson and Johnson; Financial Interests, Institutional, Other, Patent: Johnson and Johnson. S. Thomas: Financial Interests, Institutional, Full or part-time Employment: Janssen R&D; Financial Interests, Institutional, Stocks or ownership: Janssen R&D. J. Greshock: Financial Interests, Institutional, Full or part-time Employment: Janssen R&D; Financial Interests, Institutional, Stocks or ownership: Johnson and Johnson. Q. Xia: Financial Interests, Institutional, Full or part-time Employment: Janssen R&D, Geron; Financial Interests, Institutional, Stocks or ownership: Janssen R&D, Geron; Financial Interests, Institutional, Other, Travel, accomodations, expenses: Janssen R&D, Geron. J. Paone: Financial Interests, Institutional, Full or part-time Employment: Aetion Inc. P. Sheridan: Financial Interests, Institutional, Full or part-time Employment: Aetion Inc. S. Pant: Financial Interests, Institutional, Advisory Role: Zymeworks, Ipsen, Novartis, Janssen; Financial Interests, Institutional, Research Funding: Mirati Therapeutics, Mirati Therapeutics, Lilly, Xencor, Novartis, Rgenix, Bristol Myers Squibb, Astellas Pharma, Purple Biotech, 4D Pharma, Boehringer Ingelheim, NGM Biopharmaceuticals, Janssen, Arcus Biosciences, Elicio Therapeutics. C. Massard: Financial Interests, Institutional, Speaker, Consultant, Advisor: Amgen, Astellas Pharma, AstraZeneca, Bayer, BeiGene, Bristol Myers Squibb, Celgene, Debiopharm Group, Genentech/Roche, Ipsen, Janssen R&D, Lilly, MSD, Novartis, Pfizer, Sanofi, Orion, Taiho Pharmaceutical, Blueprint Medicines, Innate Pharma, PharmaMar, Faron Pharmaceuticals. D.A. Reardon: Financial Interests, Institutional, Advisory Role: Merck, Novocure, Regeneron, Bristol Myers Squibb, Oncorus, Agenus, EMD Serono, Merck KGaA, Taiho Pharmaceuticals, Delmar Pharmaceuticals, Advantagene, Bayer, Imvax, Medicenna, Vivacitas Oncology, Anheart Therapeutics, Ellipses Pharma, Genenta Science, Kintara Therapeutics, Kiyatec, Agios; Financial Interests, Institutional, Research Funding: Celldex, Incyte, Agenus, EMD Serono, Acerta Pharma, Omniox, Enterome; Financial Interests, Institutional, Other, Honoraria: Merck, Novocure, Regeneron, Bristol Myers Squibb, Oncorus, Agenus, EMD Serono, Merck KGaA, Taiho Pharmaceutical, Advantagene, Bayer, DelMar Pharmaceuticals, Imvax, Medicenna, Sumitomo Dainippon Pharma, Vivacitas Oncology, Anheart Therapeutics, Deciphera, Ellipses Pharma, Genenta Science, Inovio Pharmaceuticals, Kintara Therapeutics, Kiyatec, Neuvogen, Taiho Pharmaceutical, Y-mAbs Therapeutics. Y. Loriot: Financial Interests, Personal, Advisory Board: Merck Kga, Pfizer, Gilead, Seattle Genetics, Tahio; Financial Interests, Personal, Other, lectures, advisory boards: MSD, AstraZeneca, Astellas, Janssen; Financial Interests, Personal, Other, lectures, advisroy boards: Roche, BMS; Financial Interests, Institutional, Research Grant: Janssen, Sanofi, MSD, Roche, Celsius; Financial Interests, Institutional, Steering Committee Member: Janssen; Financial Interests, Steering Committee Member: MSD, Astellas, Gilead/Immunomedics, Tahio; Financial Interests, Personal, Steering Committee Member: basilea; Financial Interests, Institutional, Local PI: Pfizer, MSD, Janssen, Exelexis, AstraZeneca, Pfizer, Merck Kga, BMS, Astellas, Gilead, Incyte; Financial Interests, Institutional, Coordinating PI: Janssen; Non-Financial Interests, Member: ESMO, ASCO, AACR; Non-Financial Interests, Other, scientific committee: ARC. M.H.H. Schuler: Financial Interests, Institutional, Advisory Role: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Roche, Takeda, Amgen, GSK, Merck Serono, Sanofi, Janssen Oncology; Financial Interests, Institutional, Research Funding: Bristol Myers Squibb, AstraZeneca; Financial Interests, Institutional, Other, Honoraria: Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Amgen, Janssen-Cilag.
Resources from the same session
197P - Clinical benefit of HER2-targeted therapies versus prior chemotherapy in refractory HER2 expressing and mutant gastrointestinal malignancies
Presenter: Vishesh Khanna
Session: Poster session 01
198P - Detection of ERBB2 (HER2) amplification by next-generation sequencing (NGS) in patients (pts) with gastrointestinal (GI) cancer
Presenter: Yunxiang Qi
Session: Poster session 01
199P - Novel machine learning (ML) algorithm to predict immunotherapy response in small cell (SCLC) and non-small cell (NSCLC) lung cancer
Presenter: Lakshya Sharma
Session: Poster session 01
200P - Precise tumor & patient selection for CDR404: A bispecific & bivalent MAGE-A4 T cell engager
Presenter: Giorgia Giacomazzi
Session: Poster session 01
201P - Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study
Presenter: Lore Decoster
Session: Poster session 01
202P - Participant perceptions and mammography adherence from DETECT-A: The first prospective interventional trial of a multi-cancer early detection (MCED) blood test
Presenter: Nicholas Papadopoulos
Session: Poster session 01
203P - Genomic characterization of sporadic MET amplified non-small cell lung cancer (NSCLC) and association with real-world outcomes
Presenter: Ryan Gentzler
Session: Poster session 01
204P - Performance assessment of a comprehensive genomic profiling (CGP) NGS kit across multiple study laboratories
Presenter: Jonathan Choi
Session: Poster session 01
205P - A novel immunoprecipitation/PCR method for detection of plasma cfDNA fragments selectively occupied by CTCF in cancer
Presenter: Dorian Pamart
Session: Poster session 01
206P - WAYFIND-R: A global, real-world database of patients (pts) with a solid tumour profiled with next-generation sequencing (NGS)
Presenter: Jean-Yves Blay
Session: Poster session 01